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JUST SAY NO: THE CASE AGAINST THE RECLASSIFICATION 
of BUPRENORPHINE  
 
Ameet Sarpatwari, Ph.D., M.Phil.* 
“These three concerns—for individual functioning, public safety, and 
public health—provide the rationale for . . . treatment. They anchor 
the policy discussion in the recognition that multiple and competing 
objectives are being pursued. This recognition should help to achieve 





George C. sits inside the cramped examination room of Dr. 
Michael Hayes, Director of the Detoxification Center at Maryland 
General Hospital in West Baltimore.
2
 A once promising three-sport 
high school athlete, he turned to heroin following his mother’s death in 
1978.
3
 Following over eighteen attempts at treatment, George finally 
concluded that methadone would be of no help to him.
4
 It simply put 
him in a daze: “I started getting methadone in the disco era and woke 
up from it when it was hip-hop.”5 However, in 2001, Dr. Hayes intro-
                                                          
* Honorary Research Fellow, Barts and The London School of Medicine and 
Dentistry, London, United Kingdom; B.A. 2003, University of Virginia; M.Phil. 
2006, University of Cambridge; Ph.D. 2010, University of Cambridge; J.D. Candi-
date 2013, University of Maryland Francis King Carey School of Law. The author 
would like to thank Professors Richard C. Boldt and Ellen M. Weber for their inval-
uable guidance in shaping this project and his parents for their unwavering support.  
1
 COMM. ON FED. REG. OF METHADONE TREATMENT, DIVISION OF 
BIOBEHAVIORAL SCI. & MENTAL DISORDERS, INST. OF MED., FEDERAL REGULATION 
OF METHADONE TREATMENT 21 (Richard A. Rettig & Adam Yarmolinksy eds., 
1995).  
2
 Stephen Janis, Wonder Drug: Buprenorphine’s Advocates Say it Could Revo-
lutionize Addiction Treatment Here in the Nation’s Heroin Capital and Wonder Why 
it’s Taking So Long, BALT. CITY PAPER (Mar. 24, 2004), 






 Id. While dizziness and drowsiness are recognized side effects of both meth-
adone and buprenorphine, see Rasmin Benyamin et al., Opioid Complications and 
Side Effects, 11 PAIN PHYSICIAN, S105, S105 (2008), most patients do not experience 
either symptom once they have reached an appropriate, stable dose. See Brief for Re-
spondents at 37– 38, N.Y. City Transit Authority v. Beazer, 440 U.S. 568 (1979) 
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duced George to buprenorphine.
6
 The sublingually administered partial 
opioid agonist changed his life.
7
 It not only helped him minimize his 
cravings but also afforded him freedom and stability, which enabled 
him to create his own home-improvement business.
8
 George now visits 
the Hospital once a month to pick up his prescription, which he notes 
is “no different than taking [his] anti-depressant medication."9  
The Substance Abuse and Mental Health Services Administra-
tion (“SAMHSA”) estimates that 359,000 Americans age twelve years 
or older were, like George, heroin dependent or abusive in 2010, a 
67.8% increase from 2002.
10
 An additional 1.9 million people were 
                                                                                                                                         
(No. 77-1427) (noting that the directors of all the major methadone treatment pro-
grams in New York “unanimously affirmed, that after a short adjustment period, per-
sons maintained on methadone exhibit no side effects of consequence and are entire-
ly capable of normal functioning”). The primary focus of this Comment is to 
evaluate the public health impact that buprenorphine reclassification would have and, 
thus, on the decreased convenience and increased stigma of buprenorphine treatment, 
not its comparative side effects.    
6
 Janis, supra note 2. In the United States, Reckitt Benckiser markets bupren-
orphine as Subutex or Suboxone (one part naloxone per four parts buprenorphine). 
Press Release, Reckitt Benckiser, US FDA Marketing Approval for Reckitt Benck-
iser's Subutex & Suboxone (Oct. 9, 2002), available at 
http://www.rb.com/site/RKBR/Templates/MediaInvestorsGeneral2.aspx?pagei
d=168&cc=GB. In 2009, the FDA licensed Roxane Laboratories to manufacture ge-
neric Subutex. Drugs, U.S. FOOD & DRUG ADMIN., 
http://ww.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelop
edandAproved/DrugandBiologicalApprovalReports/ANDAGenericDrugApprovals/u
cm189606.htm (last visited Dec. 30, 2011).        
7
 Janis, supra note 2. An agonist is a drug that is able to activate a cellular re-
ceptor owing to its resemblance to the natural transmitter or hormone. PETER N. 
BENNETT ET AL., CLINICAL PHARMACOLOGY 76 (10th ed. 2010). A partial agonist, 
meanwhile, exhibits agonistic and antagonistic properties, resulting in a lower re-
sponse at full receptor occupancy. Id. at 77. “An opioid is any agent that activates 
opioid receptors,” and therefore includes both naturally (e.g., opium) and synthetical-
ly (e.g., heroin) derived products. What is the Difference Between “Opioids” and 
“Opiates,” The Nat’l Alliance of Advocates for Buprenorphine Treatment, 
http://www.naabt.org/faq_answers.cfm?ID=3 (last visited Dec. 30, 2012).          
8




 CTR. BEHAV. HEALTH STAT. & QUALITY, SUBSTANCE ABUSE & MENTAL 
HEALTH SERV. ADMIN., RESULTS FROM THE 2010 NATIONAL SURVEY ON DRUG USE 
AND HEALTH: SUMMARY OF NATIONAL FINDINGS 72 (2011) [hereinafter CBHSQ-
SAMHSA], available at 
http://oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.pdf. Results.pdf. CBHSQ-
SAMHSA defines substance dependence and abuse in accordance with the Diagnos-
tic and Statistical Manual of Mental Disorders, Fourth Edition (“DSM-IV”). Id. at 
69. The DSM-IV, in turn, defines these terms as follows:    
Substance Dependence: “A maladaptive pattern of substance use, leading to 
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dependent on or abusive of prescription pain-relievers,
11
 predominant-
ly opioids like hydrocodone (e.g., Vicodin) and oxycodone (e.g., 
Oxycontin), and meperidine (e.g., Demerol).
12
  Despite these figures, 
available pharmacotherapies for opioid-dependent individuals remain 
largely limited to methadone or buprenorphine.
13
 Whereas treatment 
with the Schedule II controlled substance, methadone, is heavily regu-
lated and restricted to approved programs and hospital-based pharma-
cies, Congressional enactment of the Drug Addiction Treatment Act of 
2000 (“DATA”) enabled office-based physicians to receive certifica-
tion to prescribe the Schedule III controlled substance, buprenor-
phine.
14
 Proponents of DATA argue that it effectively removed two 
                                                                                                                                         
clinically significant impairment or distress, as manifested by three (or more) of the 
following occurring at any time in the same 12-month period: 1. tolerance, as defined 
by either of the following: a. a need for markedly increased amounts of the substance 
to achieve intoxication or desired effect[,] b. markedly diminished effect with con-
tinued use of the same amount of the substance[;] 2. withdrawal, as manifested by 
either of the following: a. the characteristic withdrawal syndrome for the substance . 
. . [,] b. the same of (or a closely related) substance to relieve or avoid withdrawal 
symptoms[;] 3. the substance is often taken in larger amounts or over a longer period 
than was intended[;] 4. there is a persistent desire or unsuccessful efforts to cut down 
or control substance use[;] 5. a great deal of time is spent in activities necessary to 
obtain the substance . . . , use the substance . . . , or recover from its effects[;] 6. im-
portant social, occupational, or recreational activities are given up or reduced be-
cause of substance use[;] 7. the substance use is continued despite knowledge of hav-
ing had a persistent or recurrent physical or psychological problem that was likely to 
have been caused or exacerbated by the substance . . . .” AM. PSYCHIATRIC ASS’N, 
DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS 181 (4th ed. 2000).    
Substance Abuse: “A. A maladaptive pattern of substance use leading to clini-
cally significant impairment or distress, as manifested by one (or more) of the fol-
lowing occurring at any time during the same 12-month period: 1. recurrent sub-
stance use resulting in a failure to fulfill major role obligations at work, school, or 
home . . . [;] 2. recurrent substance use in situations in which it is physically hazard-
ous . . . [;] 3. recurrent substance-related legal problems . . . [;] 4. continued sub-
stance use despite having persistent or recurrent social or interpersonal problems 
caused or exacerbated by the effects of the substance . . . [and] B. The symptoms 
have never met the criteria for Substance Dependence for this class of substance.” Id. 
at 181–82.                 
11
 CBHSQ-SAMHSA, supra note 10, at 72.    
12
 See DrugFacts: Prescription and Over-the-Counter Medications, NAT’L 
INST. ON DRUG ABUSE, http://www.nida.nih.gov/infofacts/painmed.html (last visited 
Dec. 30, 2012).    
13
NIDA InfoFacts: Heroin, NAT’L INST. ON DRUG ABUSE, 
http://www.nida.nih.gov/infofacts/heroin.html (last visited Dec. 30, 2012).  
14
 See Ellen M. Weber, Failure of Physicians to Prescribe Pharmacotherapies 
for Addiction: Regulatory Restrictions and Physician Resistance, 13 J. HEALTH 
CARE L. & POL’Y 49, 53 (2010).  
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major obstacles to the treatment of opioid dependence: inconvenience 
and social stigma.
15
 However, the specter of buprenorphine reschedul-
ing has reappeared as a result of recent media focus on diversion,
16
 the 
use of prescription drugs for illicit recreational purposes. 
This Comment aims to examine the true extent of buprenor-
phine diversion and, thus, the public health impact that its reclassifica-
tion as a Schedule II controlled substance would likely have. Part I de-
tails the increasing dependence on and abuse of opioids among 
vulnerable populations in the United States (“U.S.”).17 Part II contex-
tualizes this growing public health crisis, tracing the increased crimi-
nalization of narcotics by the federal government in the Twentieth 
Century.
18
 Narrowing this scope, Part III elaborates upon on the emer-
gence of buprenorphine,
19
 its comparative advantage over methadone 
in the treatment of opioid dependence,
20
 and its treatment within the 
aforementioned regulatory regime.
21
 Finally, in Part IV, this Comment 
concludes by assessing the scope of buprenorphine diversion, using a 
cost-benefit calculus to demonstrate that the detrimental impact of re-
scheduling on patients like George and society at large heavily out-




I.  OPIOID DEPENDENCE & ABUSE: AN ESCALATING  
NATIONAL PROBLEM 
 
Opioid dependence and abuse is both a significant and growing 
public health concern in the U.S. As highlighted above, SAMHSA es-
timates that 359,000 Americans age twelve-years or older were heroin 
dependent or abusive in 2010, a 67.8% increase from 2002.
23
 An esti-
                                                          
15
 See id. at 54.  
16
 See Abby Goodnough & Katie Zezima, When Children’s Scribbles Hide a 
Prison Drug, N.Y. TIMES, May 27, 2011, at A1; infra Part IV.A.  
17
 See infra Part I.  
18
 See infra Part II. In ordinary parlance, the term “narcotics” is synonymous 
with “drugs,” which includes the active elements of opium poppy and coca (i.e., opi-
um and cocaine, respectively) and their derivatives. TROY DUSTER, THE 
LEGISLATION OF MORALITY: LAW, DRUGS, AND MORAL JUDGMENT 30–31 (1970).           
19
 See infra Part III.A. 
20
 See infra Part III.B. 
21
 See infra Part III.C. 
22
 See infra Part IV. 
23
 CBHSQ-SAMHSA, supra note 10, at 72. CBHSQ-SAMHSA admittedly 
does not specify whether this increase in heroin-dependent or abusive Americans is 
statistically significant (i.e., whether one can state with a predefined level of certain-
ty that the difference in the proportion of heroin-dependent or abusive individuals 
between 2010 and 2002 is real and not due to chance). See id. Regardless, a growing 
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mated 417,000 members of this cohort, moreover, received treatment 
for heroin use during this time.
24
 Although the proportion of first-time 
users did not significantly differ between 2009 and 2010, the mean age 
at first-use significantly declined (i.e., 25.5 vs. 21.3 years, respective-
ly),
25
 creating a longer window of opportunity for the development of 
addiction and, consequentially, infections associated with intravenous 
drug use such as human immunodeficiency virus (“HIV”), hepatitis C 
(“HCV”), and endocarditis. 
The burden of heroin abuse and dependence, moreover, has 
been disproportionally borne by vulnerable segments of society. In a 
cross-sectional investigation utilizing data from the Self-Help in Elim-
inating Life-threatening Diseases (“SHIELD”) Study and the U.S. 
Census, Williams and Latkin uncovered a significant positive associa-
tion (Odds Ratio [OR] [95% Confidence Interval (CI)] = 1.59 [1.06–
2.15]) between neighborhood poverty and heroin, crack, or cocaine use 
in Baltimore, Maryland.
26
 They further observed that social support 
and ties to employed persons were independently protective of such 
use (ORs [95% CIs] = 0.80 [0.69–0.92] and 0.47 [0.24–0.92], respec-
tively),
27
 underscoring the strong socioeconomic dimension to the 
problem.
28
 Indeed, the vicious cycle of social isolation associated with 
heroin use has been hypothesized to explain, at least in part, the find-
                                                                                                                                         
problem may be defined in both absolute (e.g., numbers) and relative (e.g., propor-
tions) terms. Indeed, absolute measures are on occasion more important for public 
health practitioners, who are often charged with allocating scarce resources for the 
greatest good. See generally Tanja A.J. Howeling et al., Using Relative and Absolute 
Measures for Monitoring Health Inequalities: Experiences from Cross-National 
Analyses on Maternal and Child Health, 6 INT’L J. EQUITY HEALTH 15 (2007). 
24
 CBHSQ-SAMHSA, supra note 10, at 78. 
25
 Id. at 52.  
26
 Chyvette T. Williams & Carl A. Latkin, Neighborhood Socioeconomic Sta-
tus, Personal Network Attributes and Use of Heroin and Cocaine, 32 AM. J. 
PREVENTIVE MED. S203, S203 (2007). “If the underlying statistical model is correct 
and there is no bias, a confidence interval derived from a valid analysis will, over un-
limited repetitions of the study, contain the true parameter with a frequency no less 
than its confidence level (often 95% is the stated level, but other levels are also 
used).” A DICTIONARY OF EPIDEMIOLOGY 49 (Miquel Porta ed., Oxford University 
Press 5th ed. 2008) [hereinafter DICTIONARY OF EPIDEMIOLOGY]. 
27
 Williams, supra note 26, at S203.    
28
 Opioid dependence and abuse among pregnant women raises a unique and 
complex collection of issues, including sexism, racism, and the best interests of both 
the fetus and existing sibling(s).   For an excellent and comprehensive overview of 
these topics, see Ellen M. Weber, Child Welfare Interventions for Drug-Dependent 
Pregnant Women: Limitations of a Non-Public Health Response, 75 U.M.K.C. L. 
REV. 790 (2007).     
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ing that heroin users are nearly fourteen times more likely to commit 
suicide than their peers.
29
   
Equally powerful has been the role of race. Evidence suggests 
that the rates of illicit drug use among African Americans and whites 
are comparable.
30
 However, Cooper et al. reported that the former co-
hort was 1.4 to 3.7 times more likely than the latter to engage in injec-
tion drug use in urban areas.
31
 While this discrepancy may be ex-
plained in part by socioeconomic differences, there exist gross and 
unconscionable racial disparities in the rates of arrest and imprison-
ment for drug offenses.
32
 In a 2008 study, Human Rights Watch re-
ported that African Americans constituted 53.5% of all persons im-
prisoned for drug offenses in 2003 despite comprising only 12.8% of 
the total population.
33
 Notably, African American males were roughly 
twelve times more likely to face jail time for such offenses than their 
white counterparts.
34
 As Professor Michael Tonry notes,  
 
Urban black Americans have borne the brunt of 
the War on Drugs. They have been arrested, 
prosecuted, convicted, and imprisoned at in-
creasing rates since the early 1980s, and grossly 
out of proportion to their numbers in the general 
population or among drug users. By every 
standard, the war has been harder on blacks 
than on whites; that this was predictable makes 
it no less regrettable.
35
         
                                                          
29
 Shane Darke & Jonathan Ross, Suicide Among Heroin Users: Rates, Risk 
Factors, and Methods, 97 ADDICTION 1383, 1385 (2002).  
30
 See CBHSQ-SAMHSA, supra note 10, at 21. 
31
 Hannah Cooper et al., Racial/Ethnic Disparities in Injection Drug Use in 
Large US Metropolitan Areas, 15 ANNALS EPIDEMIOLOGY 326, 331 (2005).  
32
 See RYAN S. KING, THE SENT’G PROJECT, DISPARITY BY GEOGRAPHY: THE 
WAR ON DRUGS IN AMERICA’S CITIES (2008), available at 
http://sentencingproject.org/doc/publications/dp_drugarrestreport.pdf; but see Erik 
Eckholm, Reports Find Racial Gaps in Drug Arrests, N.Y. TIMES (May 6, 2008), 
http://www.nytimes.com/2008/05/06/us/06disparities.html (noting one expert who 
“said it made sense for police to focus more on fighting visible drug dealing in low-
income urban areas, largely involving members of minorities, than on hidden use in 
suburban homes, more often by whites, because the urban street trade is more associ-
ated with violence and other crimes and impairs the quality of life”).        
33
 See HUMAN RIGHTS WATCH, TARGETING BLACKS 4 (2008), available at 
http://www.hrw.org/en/node/62236/section/8.    
34
 Id.  
35
 MICHAEL H. TONRY, MALIGN NEGLECT–RACE, CRIME, AND PUNISHMENT IN 
AMERICA 105 (1995).    
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In recent years, the opioid epidemic has been fuelled by an in-
creased misuse of prescription pain-relievers. SAMHSA estimates that 
1.9 million Americans twelve years or older were prescription pain-
reliever dependent or abusive in 2010;
36
 745,000 people, moreover, re-
ceived treatment for prescription pain-reliever use during this time.
37
 
Troublingly, the popularity of these drugs among adolescents and 
young adults appears high.
38
 The Monitoring the Future Project report-
ed the annual prevalence of Vicodin and Oxycontin use to be 8.0% and 
5.1% among twelfth-graders, respectively.
39
 Only marijuana was mis-
used more frequently.
40
 In evaluating trends in the use of prescription 
pain-relievers since 1975, the group concluded, “While the rise in use 
appears to have halted, most rates remain reasonably near to recent 
peak levels . . . . [C]learly use of most . . . narcotics other than heroin . 
. . has become a larger part of the nation’s drug abuse problems.”41  
The aggregate cost of such dependence and abuse is staggering. 
Mark et al. calculated that heroin addiction resulted in $21.9 billion in 
lost productivity and associated criminal, medical, and social welfare 
costs in 1996 alone.
42
 Birnbaum et al., meanwhile, conservatively es-
timated that prescription pain-reliever misuse costs totalled $8.6 bil-
lion in 2006.
43
 While opioid dependence and abuse has, thus, imparted 
an unequivocally heavy financial toll, the unquantifiable pain and suf-
fering it has inflicted on addicts and their friends and family may con-
stitute its greatest cost of all. Marie-Louise Kenny, who lost two of her 
brothers to overdoses within the span of three weeks, powerfully cap-
tured this sentiment, observing that “[h]eroin destroys lives. Not only 
                                                          
36
 CBHSQ-SAMHSA, supra note 10, at 72. 
37
 Id. at 78.  
38
 See Wilson M. Compton & Nora D. Volkow, Major Increases in Opioid 
Analgesic Abuse in the United States: Concerns and Strategies, 81 DRUG & 
ALCOHOL DEPENDENCE 103, 104 (2006) (noting that “opioid analgesic abuse is 
mostly concentrated in adolescents and young adults”).    
39
 LLOYD D. JOHNSTON ET AL.; MONITORING THE FUTURE; NATIONAL SURVEY 
RESULTS ON DRUG USE, 1975–2010–VOLUME I: SECONDARY SCHOOL STUDENTS 
2010 22 (2011).       
40
 Compton & Volkow, supra note 38, at 103.  
41
 JOHNSTON ET AL., supra note 39, at 23.     
42
 Tami L. Mark et al., The Economic Costs of Heroin Addiction in the United 
States, 61 DRUG & ALCOHOL DEPENDENCE 195, 203 (2001).  
43
 Howard G. Birnbaum et al., Estimated Costs of Prescription Opioid Analge-
sic Abuse in the United States in 2001: A Societal Perspective, 22 CLINICAL J. PAIN 
667, 671 (2006).  
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the lives of the people who take it, but the future of those who are left 
behind.”44   
     
II. NARCOTIC REGULATION IN THE UNITED STATES: A CRIMINALIZED 
DRUG POLICY 
 
A. The Harrison Act, Doremus & Webb: Opening  
the Door to Federal Intervention 
 
Over the course of the Twentieth Century, however, the federal 
government adopted and strengthened a drug policy that emphasized 
prohibition and criminalization over public health.
45
 Congress laid its 
foundation with passage of the Harrison Narcotics Act of 1914 (“Har-
rison Act”), which “required manufacturers and sellers of narcotics to 
register with the federal government and to pay a tax on each transac-
tion.”46 Despite explicitly permitting physicians, dentists, and veteri-
narians to continue prescribing such drugs in the course of their pro-
fessional practice,
47
 the Harrison Act was quickly interpreted as a 
prohibitionist tool by its enumerated enforcers, the Department of the 
Treasury, which “[staked] out the position that the administration of 
drugs by a physician to an addict in order to prevent the suffering of 
physical withdrawal was not the good-faith practice of medicine.”48 
Professor Troy Duster highlights the sudden and seemingly drastic na-
ture of this policy shift, remarking that only years earlier “anyone 
could go to his corner druggist and buy grams of morphine or heroin 
for just a few pennies.”49 Scholars theorize that a host of influences 
likely contributed to this newfound approach to narcotics regulation, 




The Supreme Court wasted little time wading into the debate, 
deciding the companion cases United States v. Doremus and Webb v. 
                                                          
44
 MARY KENNY, DEATH BY HEROIN: RECOVERY BY HOPE 22 (2000).  
45
 For an illuminating and rigorous discussion of the divergence of U.S. drug 
policy from that of the United Kingdom in the 20th Century, see Richard C. Boldt, 
Drug Policy in Context: Rhetoric and Practice in the United States and the United 
Kingdom, 62 S.C. L. REV. 261 (2011).    
46
 Id. at 274.  
47
 Harrison Narcotics Act of 1914, Pub. L. No. 63-223, 38 Stat. 785, 786, re-
pealed by Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. L. 
No. 91-513, 84 Stat. 1236 (codified as amended at 21 U.S.C. §§ 801–971 (2006)).    
48
 Boldt, supra note 45, at 279–80.     
49
 DUSTER, supra note 18, at 3.  
50
 See Boldt, supra note 45, at 269–77.     
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United States in 1919.
51
 In Doremus, the federal government brought 
charges against a registered physician for issuing heroin to a patient in 
maintenance of his addiction.
52
 The Court held that the Harrison Act 
constituted a valid exercise of Congressional Power under Article I, 
Section 8 (i.e., the Taxing and Spending Clause) of the Constitution 
and, in so doing, gave at least tacit approval to the prohibitory preroga-
tive of the Department of the Treasury: “The act may not be declared 
unconstitutional because its effect may be to accomplish another pur-
pose as well as the raising of revenue.”53 The Court was more explicit 
in Webb, in which the defendant-appellant regularly sold morphine to 
habitual users.
54
 The United States Court of Appeals for the Sixth Cir-
cuit had posed for the Justices the following question:  
 
If a practicing and registered physician issues 
an order for morphine to an habitual user there-
of, the order not being issued by him in the 
course of professional treatment in the attempt-
ed cure of the habit, but being issued for the 
purpose of providing the user with morphine 
sufficient to keep him comfortable by maintain-
ing his customary use, is such order a physi-
cian's prescription under exception (b) of [Sec-




Speaking for the Court, Justice Day responded firmly in the negative, 
holding that “to call such an order for the use of morphine a physi-
cian's prescription would be so plain a perversion of meaning that no 
discussion of the subject is required.”56 As Professor Ellen Weber 
notes, these companion rulings effectively precluded the ambulatory 





                                                          
51
 See 249 U.S. 86 (1919); 249 U.S. 96 (1919).    
52
 Doremus, 249 U.S. at 90.  
53
 Id. at 94.  
54
 Webb, 249 U.S. at 97–98.  
55
 Id. at 99.  
56
 Id. at 99–100.    
57
 Weber, supra note 14, at 60 n.70 (citing DAVID F. MUSTO, THE AMERICAN 
DISEASE 119–20 (3d. ed. 1999)); but see United States v. Jin Fuey Moy, 241 U.S. 
394, 402 (1916) (holding that the Harrison Act did not bar a physician from issuing 
morphine to a patient addicted to opium only three years earlier).    
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B. The War on Drugs: A Further Rejection of Medicalization 
 
The federal movement rejecting the medicalization of opioid 
dependence and abuse gained intensity over the following decades.
58
 
In 1930, the Department of the Treasury consolidated the functions of 
the Federal Narcotics Control Board and the Narcotic Division under 
the newly created Federal Bureau of Narcotics (“FBN”), selecting Har-
ry J. Anslinger as its first commissioner.
59
 Over his thirty-two-year 
reign, Anslinger championed a highly criminalized U.S. drug policy, 
effectively lobbying Congress to create federal “narcotics farms,” 
criminalize the sale of cannabis, and enact harsh mandatory minimum 
prison sentences for drug offenses.
60
 The American Medical Associa-
tion (“AMA”) and American Bar Association (“ABA”) lamented the 
resulting dearth of resources for the study of opioid dependence and 
abuse amidst this regulatory climate, noting in a joint 1961 report:  
 
The narcotic drug addict because of his 
physical and psychological dependence on 
drugs and because of his frequently abnormal 
personality patterns should be as much a subject 
of concern to medicine and public health as to 
those having to do with law enforcement. But 
the ordinary doctor is not presently well 
equipped to deal with the problems of the nar-
cotic addict, and even his authority to do so is in 
doubt. 
The role of medicine and public health 
in dealing with drug addiction and the drug ad-
dict should be clarified. There must be a new 
determination of the limits of good medical 
practice in the treatment of drug addiction, and 
an objective inquiry into the question whether 
existing enforcement policies, practices and at-
titudes, as well as existing laws, have unduly or 
improperly interfered with good medical prac-
tice in this area. As part of this evaluation, con-
                                                          
58
 Boldt, supra note 45, at 285.     
59
 LESLEY STONE & SUSAN C. KIM, Domestic Public Health Law, in 
PRINCIPLES OF ADDICTIONS AND THE LAW: APPLICATIONS IN FORENSIC, MENTAL 
HEALTH, AND MEDICAL PRACTICE 97, 99 (2010).  
60
 Id. at 99–101.  
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sideration should also be given to the possibility 
of helping both the addict and persons formerly 
addicted through open clinic facilities as well as 
in closed institutions such as Lexington and 
Fort Worth.
61
   
 
Instead of heeding these recommendations, however, the feder-
al government heightened its assault, culminating in President Richard 
Nixon’s infamous declaration of “War on Drugs” and passage of the 
Comprehensive Drug Abuse Prevention and Control Act of 1970 
(“CDAPCA”).62 CDAPCA replaced the Harrison Act and classified 
narcotics into five schedules (i.e., Schedules I–V) according to their 
abuse and treatment potentials and their psychological and physiologi-
cal effects.
63
 Whereas Schedule I controlled substances are a) easily 
abused, b) not generally accepted for treatment, and c) widely per-
ceived as unsafe;
64
 Schedule V controlled substances a) have a low po-
tential for abuse, b) are commonly used in treatment, and c) demon-
strate a minimal risk of dependence.
65
 Narcotics classed within higher 
schedules are subject to increased restrictions; therefore, while pheno-
barbital, a Schedule IV controlled substance, may be prescribed to and 
refilled by patients up to five times within a six-month period,
66
 no 
prescriptions are permitted for the Schedule I narcotic, heroin.
67
 Nota-
bly, authority for the classification of drugs under the CDAPCA rests 
with the Drug Enforcement Agency (“DEA”), acting under the auspi-
ces of the Department of Justice (“DOJ”) and not the Department of 
Health and Human Services (“HHS”).68 Although Congress has subse-
                                                          
61
 C. JOSEPH STETLER ET AL., JOINT COMM. OF THE AM. BAR ASS’N & THE AM. 
MED. ASS’N, DRUG ADDICTION, CRIME OR DISEASE? FINAL REPORT OF THE JOINT 
COMMITTEE OF THE AMERICAN BAR ASSOCIATION AND THE AMERICAN MEDICAL 
ASSOCIATION ON NARCOTIC DRUGS 3 (1961) (internal numbering omitted), available 
at http://druglibrary.net/schaffer/Library/studies/dacd/final_report.htm.  
62
 Boldt, supra note 45, at 286.     
63
 The Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. 
L. No. 91–513, 84 Stat. 1236, 1247–52 
64
 21 U.S.C. §§ 812(b)(1)(A–C) (2006).  
65
 Id. §§ 812(b)(5)(A–C).  
66
 See id. § 829(b)(2)(E).  
67
 See id. § 829.  
68
 See 21 C.F.R. § 1308.42 (2012); 21 U.S.C. § 811(a). In making a determina-
tion, the DEA must evaluate eight factors: the a) history of and b) potential for abus-
ing the narcotic; c) the severity of this abuse; the narcotic’s d) pharmacological ef-
fects, e) risk of dependence, and f) threat to public health; g) the regulatory status of 
its successor substance; and g) the depth of the existing evidence base. 21 U.S.C. §§ 
811(c)(1–8).    
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quently modified CDAPCA,
69
 its substance remains largely intact to-
day.
70
       
III.  BUPRENORPHINE 
 
A. Emergence of a Novel Treatment 
 
Near the peak of this war, a promising new drug arrived on the 
scene.
71
 In 1981, the FDA granted the pharmaceutical company 
Reckitt Coleman, now Reckitt Benckiser, approval to market the par-
tial opioid agonist, buprenorphine, as a hospital-based analgesic.
72
 By 
this time, researchers had already documented its potential as a possi-
ble alternative to methadone; Drs. Nancy Mello and Jack Mendelson, 
for example, reported a statistically significant (p < 0.001), dose-
dependent reduction in heroin use in a ten day randomized controlled 
trial (“RCT”) among ten heroin-dependent men.73 Nevertheless, it was 
not until 2002 that the FDA officially indicated buprenorphine for the 
treatment of opioid dependence.
74
 
In October that year, Reckitt Benckiser received licensing ap-
proval for two distinct high-dose buprenorphine formulations: Subutex 
and Suboxone.
75
 While Subutex consists of the single active ingredi-
ent, burprenorphine, Suboxone contains both buprenorphine and na-
                                                          
69
 See, e.g., Psychotropic Substances Act of 1978, Pub. L. No. 95–633, 92 
Stat. 3768; Controlled Substances Penalties Amendment Acts of 1984, Pub. L. No. 
98–473, 98 Stat. 2068; The Chemical Diversion and Trafficking Act of 1988, Pub. L. 
No. 100–690, 102 Stat. 4312.  
70
 Compare The Comprehensive Drug Abuse Prevention and Control Act of 
1970, Pub. L. No. 91–513, 84 Stat. 1236, 1242–84, with 21 U.S.C. §§ 801–971.    
71
 Schedules of Controlled Substances: Rescheduling of Buprenorphine from 
Schedule V to Schedule III, 67 Fed. Reg. 62,354, 62,354 (Oct. 7, 2002).  
72
 Id.    
73
 Nancy K. Mello & Jack H. Mendelson, Buprenorphine Suppresses Heroin 
Use by Heroin Addicts, 207 SCIENCE 657, 658 (1980). Drs. Mello and Mendelson 
reported a 45% and 69%–98% decrease in heroin use at buprenorphine doses of four 
and eight milligrams a day, respectively. Id. An RCT is defined as “[a]n epidemio-
logical experiment in which subjects in a population are randomly allocated into 
groups . . . to receive an experimental preventive or therapeutic . . . intervention.” 
DICTIONARY OF EPIDEMIOLOGY, supra note 26, at 206. Owing to their minimization 
of bias, “RCTs are generally regarded as the most scientifically rigorous method of 
hypothesis testing available in epidemiology and medicine.” Id.       
74
 Press Release, Reckitt Benckiser, supra note 6.  
75
 Id.  
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loxone, an opioid antagonist, in a four-to-one ratio, respectively.
76
 In 
vivo studies revealed higher bioavailability of buprenorphine upon 
sublingual administration.
77
 However, naloxone proved considerably 
more potent if injected, blocking “the euphoric/analgesic effects of bu-
prenorphine in opioid-dependent individuals.”78 These findings led 
many health professionals to speculate that Suboxone would serve as 




B.  Comparative Advantage in the Treatment of Opioid Dependence 
 
Both formulations are arguably more attractive than methadone 
in the treatment of opioid dependence. First, buprenorphine exhibits 
comparable efficacy to methadone; in a head-to-head RCT of these 
drugs, Johnson et al. documented a similar percentage of participants 
with twelve or more consecutive opioid-negative urine analyses (26% 
vs. 28%, respectively) as well as analogous levels of self-reported in-
tra-study opioid use (four times per week for both cohorts) and post-
study opioid dependence (thirty-four vs. thirty-eight points, respective-
ly, on a one-hundred point scale of increasing severity).
80
 Likewise, in 
a meta-analysis of five RCTs, Drs. Linda Gowing, Robert Ali, and Ja-
son White uncovered a non-statistically significant relative risk (“RR”) 
of the completion of withdrawal among patients on both pharma-
cotherapies (RR [95% CI] = 1.18 [0.93-1.49]).
81
 
                                                          
76
 Schedules of Controlled Substances: Rescheduling of Buprenorphine from 
Schedule V to Schedule III, 67 Fed. Reg. 62,354, 62,354 (Oct. 7, 2002).  
77
 Michael A. Yokell et al., Buprenorphine and Buprenorphine/Naloxone Di-
version, Misuse, and Illicit Use: An International Review, 4 CURRENT DRUG ABUSE 
REV. 28, 30 (2011).  
78
 Id.  
79
 See Schedules of Controlled Substances: Rescheduling of Buprenorphine 
from Schedule V to Schedule III, 67 Fed. Reg. at 62,355 (summarizing comments 
submitted by both the American Society of Addiction Medicine [“ASAM”] and the 
California Society of Addiction Medicine [“CSAM”], which posited a low risk of 
Suboxone diversion).  
80
 Rolley E. Johnson et al., A Comparison of Levomethadyl Acetate, Bupren-
orphine, and Methadone for Opioid Dependence, 343 NEW ENG. J. MED. 1290, 1295 
(2000).    
81
 Linda Gowing, Robert Ali & Jason M. White, Buprenorphine for the Man-
agement of Opioid Withdrawal, 1 COCHRANE DATABASE SYSTEMATIC REV., 2009, at 
1, 13. A meta-analysis is “[a] statistical analysis of results from separate studies, ex-
amining sources of difference in results among studies, and leading to a quantitative 
summary of the results if the results are judged sufficiently similar to support such 
synthesis.” DICTIONARY OF EPIDEMIOLOGY, supra note 26, at 154. See also Richard 
P. Mattick et al., Buprenorphine Versus Methadone Maintenance Therapy: A Ran-
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Second, buprenorphine poses a smaller risk of adverse events. 
As a partial opioid agonist, it exhibits a ceiling effect or plateau of its 
agonistic effects (e.g., euphoria, sedation, and respiratory distress), 
even at high doses.
82
 Yokell et al. illustratively note that “[i]n experi-
mental settings, doses up to 70 times the recommended analgesic dose 
were well tolerated in non-dependent males who had previous experi-
ence with opioids.”83 The potential for abuse and overdose, though 




Finally, from a patient perspective, buprenorphine carries less 
social stigma and is significantly more accessible than methadone. As 
part of a recent, albeit inconsistent and fractured, movement to steer 
federal drug policy toward a more medicalized model,
85
 Congress 
passed DATA, which enabled physicians to obtain certification to pre-
scribe Schedule III, IV, and V narcotics for the treatment of opioid de-
pendence.
86
 Its impact, Professor Weber argues, has been revolution-
ary:  
 
Significantly more patients can be treated for 
opioid dependence through the prescription of 
buprenorphine in an office-based practice than 
in federally regulated opioid treatment pro-
grams that prescribe and dispense methadone. 
The patients who seek office-based care tend to 
be younger, have fewer years of opiate depend-
ence, and have lower rates of intravenous drug 
use . . . than persons who receive treatment in 
methadone programs. [They] . . . avoid both the 
stigma associated with obtaining care in a spe-
                                                                                                                                         
domized Double-Blind Trial with 405 Opioid-Dependent Patients, 98 ADDICTION 
441, 446–47 (2003) (failing to uncover a statistically significant differences in the 
intra-study percentages of morphine-free urine samples and levels of self-reported 
heroin use between opioid-dependent patients administered buprenorphine and 
methadone).        
82
 Yokell et al., supra note 77, at 29.  
83
 Id. (citing Sharon L. Walsh et al., Clinical Pharmacology of Buprenorphine: 
Ceiling Effects at High Doses, 55 CLINICAL PHARMACOLOGY & THERAPEUTICS 569, 
577 [1994]) (emphasis added).     
84
 Id. at 31.  
85
 See Boldt, supra note 45, at 345 (arguing that recent federal drug policy has 
been a “mixed picture”).  
86
 Children's Health Act of 2000, Pub. L. No. 106-310, § 3502, 114 Stat. 1101, 
1222–27 (2000) (codified at 21 U.S.C. § 823(g) (2006 & West Supp. 2009)). 
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cialty methadone clinic, and the strict daily at-
tendance regimen imposed on patients . . . . Fi-
nally, the co-location of addiction treatment in a 





C.  Regulatory History: From Schedule V to III 
 
Despite these comparative advantages, the anticipated increase 
in diversion that would result from the expansion in indication 
prompted the DEA to re-categorize buprenorphine from Schedule V to 
Schedule III just two days prior to the release of Subutex and 
Suboxone into the market.
88
 The move was ostensibly premised on 
“numerous scientific studies” and “years of human experience.”89 Spe-
cifically, the DEA highlighted two paramount concerns. First, it 
claimed that despite posing a limited risk of physical dependence, bu-
prenorphine more closely resembles pure agonists in the subjective 
feelings of pleasure and euphoria it elicits.
90
 Second, it cited multiple 
studies that revealed that the four-to-one ratio of buprenorphine to na-
loxone in Suboxone does not effectively precipitate withdrawal symp-
toms among non-opioid dependent or abusive individuals when admin-
istered intravenously;
91
 in other words, the drug does not sufficiently 
punish people who seek to use it illicitly.      
 
IV. A COST-BENEFIT ANALYSIS: THE STRONG CASE AGAINST 
RESCHEDULING 
 
A. The Threat of Rescheduling 
 
While buprenorphine has remained a Schedule III controlled 
substance, the media has recently shone light on the issue of its diver-
sion.
92
 In May of 2011, for example, The New York Times ran a feature 
                                                          
87
 See Weber, supra note 14, at 54.  
88
 See Schedules of Controlled Substances: Rescheduling of Buprenorphine 
from Schedule V to Schedule III, 67 Fed. Reg. 62,354, 62,354 (Oct. 7, 2002); Press 
Release, Reckitt Benckiser, supra note 6.     
89
 Schedules of Controlled Substances: Rescheduling of Buprenorphine from 
Schedule V to Schedule III, 67 Fed. Reg. at 62,354.  
90
 Id. at 62,357–58.    
91
 Id. at 62,359.  
92
 See, e.g., Doug Donovan & Fred Schulte, “Bupe” Seizures Rise as Treat-
ment Use Grows, BALT. SUN (Apr. 18, 2008),  http://articles.baltimoresun.com/2008-
04-18/news/0804180065_1_buprenorphine-lab-data-seizures; Cinderella, Snow 
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story on the purportedly growing problem of Suboxone smuggling in 
prisons “from New Mexico to Maine.”93 The article quoted Major 
Francine Breton, Administrator of the Cumberland County Jail in Port-
land, Maine, who stated, “It’s become a crisis in here, to be honest 
with you. It’s the drug of choice right now.”94 Two months later, the 
Burlington Free Press echoed her concern while further highlighting 




This increased media attention followed on the heels of height-
ened inter- and intra-governmental scrutiny of the adequacy of the ex-
isting buprenorphine regulatory regime. In 2006, the World Health 
Organization (“WHO”) Expert Committee on Drug Dependence for-
mally weighed the merits of reclassifying buprenorphine from a 
Schedule III substance under the Convention on Psychotropic Sub-
stances of 1971 to a Schedule I narcotic under the Single Convention 
on Narcotic Drugs of 1961,
96
 a move that would, in the words of the 
American Psychiatric Association (“APA”), have “a chilling effect on 
access . . . to the extent that international drug scheduling influences 
individual countries’ choices of how to control buprenorphine.”97 The 
Committee justified its proffer, in part, on “reports of diversion, sei-
zures, and abuse of buprenorphine in various countries.
98
 Although the 
proposal was ultimately rejected,
99
 the federal government has subse-
quently considered a variety of steps that it can take to mitigate diver-
                                                                                                                                         




Prison Inmates Try to Smuggle Drug Via Colouring Book: Three 
Prison Inmates and Their Loved Ones Have Been Charged with Attempting to 
Smuggle Drugs into a US Jail on the Pages of a Children's Colouring Book, 
TELEGRAPH (Mar. 29, 2011), 
http://www.telegraph.co.uk/news/worldnews/northamerica/usa/8414951/Prison-
inmates-try-to-smuggle-drug-via-colouring-book.html.    
93
 See Goodnough & Zezima, supra note 16.  
94
 Id.  
95
 Sam Hemingway, Suboxone Succeeds in Aiding Opiate Addicts, but too 




 WHO EXPERT COMM. ON DRUG DEPENDENCE, THIRTY-FOURTH REPORT 5–8 
(2006).  
97
 Jim Rosack, APA Opposes WHO Proposal to Tighten Buprenorphine Con-
trols, 4 PSYCHIATRIC NEWS, March 3, 2006, at 2, 2.  
98
 WHO EXPERT COMM. ON DRUG DEPENDENCE, supra note 96, at 6. 
99
 Id. at 7–8.  
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sion.
100
 Combined, these actions raise legitimate concerns regarding 
the specter of buprenorphine reclassification as a Schedule II con-
trolled substance.     
 
B.  Diversion: More Than Meets the Eye 
 
Two facts militate against such a move. First, although bupren-
orphine diversion has been well documented, it does not rise to the 
level of significant public health concern in the U.S. In an international 
literature review, Yokell et al. uncovered data inversely tying the fre-
quency of illicit buprenorphine use to heroin accessibility.
101
 In Fin-
land, for example, “A sharp increase in the misuse of buprenorphine 
coincided with a notable decrease in 2001 in the availability of hero-
in.”102 Arguably owing to this diminished market, Aalto et al. report 
that twenty-nine of thirty opioid-dependent patients (97%) they evalu-
ated in a 2007 study listed buprenorphine as their primary drug of 
choice.
103
 Heroin, however, is readily accessible in the U.S., particu-
larly in metropolitan areas.
104
 The frequency of diversion has therefore 
been low; in fact, buprenorphine “generally ranked as the least-abused 
or misused opioid among those studied (examples of other opioids 
with higher rates of abuse in the U.S. include heroin, oxycodone, hy-
drocodone, methadone, morphine, and fentanyl).”105 
Second, the demand for diversion appears to stem principally 
from individuals who lack access to treatment and, consequentially, 
use buprenorphine therapeutically. In a recent study by Bazazi et al., 
for example, a majority of injecting and non-injecting opioid-abusers 
reported illicitly using Suboxone to reduce withdrawal symptoms.
106
 
                                                          
100
 See Doug Donovan & Fred Schulte, Strategies to Control Bupe Abuse Out-
lined, BALT. SUN (Feb. 23, 2008), http://articles.baltimoresun.com/2008-02-
23/news/0802230293_1_buprenorphine-heroin-drug-treatment.  
101
 Yokell et al., supra note 77, at 32.  
102
 Id.  
103
 Mauri Aalto et al., Buprenorphine Misuse in Finland, 42 SUBSTANCE USE 
& MISUSE 1027, 1027 (2007).    
104
 U.S. DEP’T JUSTICE NAT’L DRUG INTELLIGENCE CTR., NATIONAL DRUG 
THREAT ASSESSMENT 2 (2011).  
105
 Yokell et al., supra note 77, at 33.  
106
 Alexander R. Bazazi et al., Illicit Use of Buprenorphine/Naloxone Among 
Injecting and Noninjecting Opioid Users, 5 J. ADDICTION MED. 175, 177 (2011). See 
also Raminta Daniulaityte, Russel Falck & Robert G. Carlson, Illicit Use of Bupren-
orphine in a Community Sample of Young Adult Non-Medical Users of Pharmaceuti-
cal Opioids, 122 DRUG & ALCOHOL DEPENDENCE 201, 204 (2012) (reporting that 
half of respondents took buprenorphine illicitly to reduce withdrawal symptoms).  
Sarpatwari 2/13/2013  3:55 PM 
394 U. MD. L.J. RACE, RELIGION, GENDER & CLASS [VOL 12:2 
Although expressing a strong interest in treatment, they faced signifi-
cant barriers: “Cost and difficulty of finding a prescribing physician 
were commonly reported reasons for why interested participants were 
unable to access . . . treatment.”107 These observations are consistent 
with SAMHSA’s findings in a Vermont case study that “buprenor-
phine diversion and abuse are not widespread, but rather tend to be 
concentrated in certain small population groups within the state . . . 
[that] may reflect lack of access to addiction treatment.”108 Diversion, 
thus, appears primarily fuelled by efforts at harm reduction and may 
paradoxically be solved through greater, not reduced, access to bu-
prenorphine (i.e., outpatient-based pharmacotherapy), a prescription 
rooted in history. Increased concern over buprenorphine diversion par-
allels heightened public outcry over illicit drug use in the early Twen-
tieth Century.
109
 One influential reading of U.S. drug policy posits that 
the restrictions placed upon the ability of physicians to treat opioid de-
pendence and abuse, in at least partial response to this outcry,
110
 pre-
cipitated the development on an illegal market and, possibly, to an in-
creased number of opioid dependent individuals.
111
    
These facts clearly reveal a paucity of risk posed by buprenor-
phine diversion at present and, thus, the marginal benefits of resched-
uling that would come at the price of overwhelming costs. Not only 
would a substantially smaller number of opioid-dependent individuals 
be treated, those continuing to be so would be forced to forgo the ben-







The reclassification of buprenorphine as a Schedule II con-
trolled substance would ultimately represent a significant and damag-
ing regression in federal drug policy.
113
 Opioid-dependence and abuse 
                                                          
107
 Bazazi et al., supra note 106, at 179.  
108
 CTR. SUBSTANCE ABUSE & MENTAL HEALTH SERVICES ADMIN., 
DIVERSION AND ABUSE OF BUPRENORPHINE: A BRIEF ASSESSMENT OF EMERGING 
INDICATORS–RESULTS OF THE VERMONT CASE STUDY 5 (2006).  
109
 See Boldt, supra note 45, at 271.  
110
 See id. at 275–76.  
111
 See PETER CONRAD, DEVIANCE AND MEDICALIZATION: FROM BADNESS TO 
SICKNESS 127 (Temple Univ. Press 1992). 
112
 See Weber, supra note 14, at 54.  
113
 See supra Part II, Part III.B & Part IV.B.  
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constitutes a growing public health epidemic,
114
 which can only be 
tackled through enhanced access to pharmacotherapies.
115
 The scope 






                                                          
114
 See supra Part I.  
115
 See supra Part IV.B.  
116
 See id.  
